# OnCo record proagio (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/proagio/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "proagio" ;
  schema:name "ProAgio"@en ;
  schema:description "ProAgio is a protein drug from ProDa BioTech that targets an integrin receptor found on tumour blood vessels and the support cells around tumours. It is in an early trial with gemcitabine in triple-negative breast cancer that has spread."@en ;
  schema:url <https://onco.cc/drugs/proagio/> ;
  schema:dateModified "2026-11-04"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06460298> ;
  onco:status "phase-1" ;
  onco:tag "pipeline" ;
  onco:modality "Protein cytotoxin (anti-integrin)" ;
  onco:cancers <https://onco.cc/cancers/tnbc/> ;
  onco:sections <https://onco.cc/fronts/targeted-therapy/> ;
  onco:companies <https://onco.cc/companies/proda-biotech/> ;
  onco:trials <https://onco.cc/trials/nct06460298/> .